Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 907 results

Media Release / Jun 22, 2022

Novartis expands Beacon of Hope through alliances with Historically Black Medical Schools to address systemic health disparities

Novartis commits additional $17.7 million to create Clinical Trial Centers of Excellence at Howard University College of Medicine, Meharry Medical College and Charles R. Drew University of Medicine…
Media Release / Dec 11, 2023

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥…
Media Release / Dec 06, 2023

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH…
Media Release / Nov 24, 2023

Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Company Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 Novartis Media Relations E-mail: [email protected] North America Julie Masow …
Statement / Mar 11, 2020

Novartis provides update on use and safety of Beovu® in patients with wet AMD
Statement / Jul 16, 2018

Novartis Pharmaceuticals Corporation (Novartis) Statement on Recall Outside the United States of Sandoz Generic Valsartan and Sandoz Valsartan and Hydrochlorothiazide Film-Coated Tablets
Statement / Sep 24, 2019

Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement
Statement / Feb 12, 2020

Novartis launches new Preferred Firm Program for legal services
Statement / Feb 18, 2020

Corrective Action for Certain 100-mg SANDIMMUNE® and NEORAL® Blister Packages in the US
Statement / Apr 17, 2020

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

‹ Previous page
1
…
24
25
26
27
28
29
30
…
91
› Next page